Eli Lilly and Co  

(Public, NYSE:LLY)   Watch this stock  
Find more results for LLY
Nov 26 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week 48.88 - 68.67
Open     -
Vol / Avg. 0.00/4.26M
Mkt cap 74.96B
P/E 26.95
Div/yield 0.49/2.91
EPS 2.50
Shares 1.11B
Beta 0.44
Inst. own 77%
Jan 30, 2015
Q4 2014 Eli Lilly and Co Earnings Release - 9:30AM EST - Add to calendar
Jan 30, 2015
Q4 2014 Eli Lilly and Co Earnings Conference Call - 9:00AM EST - Add to calendar
Jan 7, 2015
Eli Lilly and Co 2015 Financial Guidance Call - 9:00AM EST - Add to calendar
Nov 12, 2014
Eli Lilly and Co at Credit Suisse Healthcare Conference
Oct 23, 2014
Q3 2014 Eli Lilly and Co Earnings Release
Oct 23, 2014
Q3 2014 Eli Lilly and Co Earnings Conference Call
Sep 17, 2014
Eli Lilly and Co at Morningstar's Management Behind the Moat Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 10.27% 20.27%
Operating margin 11.53% 23.24%
EBITD margin - 29.76%
Return on average assets 5.76% 13.45%
Return on average equity 11.26% 28.92%
Employees 39,510 -
CDP Score - 86 B


Lilly Corporate Center
United States - Map
+1-317-2762000 (Phone)
+1-317-2763492 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Eli Lilly and Company, discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 15 other countries. Its products are sold in approximately 130 countries. The Company�s products include neuroscience products, endocrinology products, oncology products, cardiovascular products, animal health products and other pharmaceuticals. The Company�s new molecular entities (NMEs) are in Phase III clinical trial testing include Dulaglutide, Edivoxetine, Empagliflozin-BI10773, Enzastaurin, Ixekizumab, Necitumumab,, New insulin glargine product, Novel basal insulin analog, Pomaglumetad Methionil, Ramucirumab, Solanezumab and Tabalumab. In July 2014, Anthera Pharmaceuticals Inc acquired Sollpura (liprotamase), a investigational Pancreatic Enzyme Replacement Therapy (PERT) from Eli Lilly and Company.

Officers and directors

John C. Lechleiter Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Derica W. Rice Chief Financial Officer, Executive Vice President - Global Services
Age: 49
Bio & Compensation  - Reuters
Maria A. Crowe President - Manufacturing Operations
Age: 54
Bio & Compensation  - Reuters
Jan M. Lundberg Ph.D. Executive Vice President - Science and Technology, President - Lilly Research Laboratories
Age: 60
Bio & Compensation  - Reuters
Melissa S. Barnes Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Age: 45
Bio & Compensation  - Reuters
Michael J. Harrington Senior Vice President, General Counsel
Age: 51
Bio & Compensation  - Reuters
Stephen F. Fry Senior Vice President - Human Resources and Diversity
Age: 48
Bio & Compensation  - Reuters
Enrique A. Conterno Senior Vice President and President - Lilly Diabetes
Age: 47
Bio & Compensation  - Reuters
Susan Mahony Ph.D. Senior Vice President and President - Lilly Oncology
Age: 49
Bio & Compensation  - Reuters
Barton R. Peterson Senior Vice President - Corporate Affairs and Communications
Age: 55
Bio & Compensation  - Reuters